Global Head of Market Access & Health Policy Roche
Join our panel as they progress and the drivers behind securing value and outcome based contracts with payers for IVDs. Reimbursement for IVD tests has consistently been based on the cost of performing the tests in the laboratory, rather than its derived value; often inconsiderate of other cost factors associated with the execution of the test. With the COVID pandemic bringing further visibility to the need and value of diagnostics, has the pursuit of value based pricing and outcomes based pricing contracts with payers gained new momentum? VBP will gain more importance in the future, however, successes to-date are still anecdotal, and challenges remain without well-structured policies in place. Our panelist will share concrete experiences and insights on payer behavior. Questions to be explored by the panel include: What is the payer mindset behind accelerating and defining standard criteria for VBP for IVDs? What role does industry play in driving broader acceptance of VBP in the IVD space? (When) Will VBP become the norm for IVD tests? What are the key criteria payers are looking at and what evidence is needed? How do you demonstrate meaningful clinical utility? What strategies can be employed until standard policies are in place?